1
|
Evans CM, Kudesia G, McKendrick M. Management of herpesvirus infections. Int J Antimicrob Agents 2013; 42:119-28. [PMID: 23820015 DOI: 10.1016/j.ijantimicag.2013.04.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Accepted: 04/24/2013] [Indexed: 12/19/2022]
Abstract
Management of human herpesviruses remains a considerable clinical challenge, in part due to their ability to cause both lytic and latent disease. Infection with the Herpesviridae results in lifelong infection, which can reactivate at any time. Control of herpesviruses is by the innate and adaptive immune systems. Herpesviruses must evade the host innate immune system to establish infection. Once infected, the adaptive immune response, primarily CD8(+) T-cells, is crucial in establishing and maintaining latency. Latent herpesviruses are characterised by the presence of viral DNA in infected cells and limited or no viral replication. These characteristics provide a challenge to clinicians and those developing antiviral agents. The scope of this review is two-fold. First, to provide an overview of all antivirals used against herpesviruses, including their mechanism of action, pharmacokinetics, side effects, resistance and clinical uses. And second, to address the management of each of the eight herpesviruses both in the immunocompetent and immunocompromised host, providing evidence for clinical management and therapeutic options, which is important to the clinician engaged in the management of these infections.
Collapse
Affiliation(s)
- Cariad M Evans
- Department of Virology, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
| | | | | |
Collapse
|
2
|
Abraham KA, O'Kelly P, Spencer S, Hickey DP, Conlon PJ, Walshe JJ. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival. Ren Fail 2008; 30:141-6. [PMID: 18300112 DOI: 10.1080/08860220701805208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
It is recognized that cytomegalovirus (CMV) infection in transplant recipients may lead to graft loss. Prophylaxis with acyclovir has therefore gained widespread acceptance, but the debate on whether this intervention improves long term graft survival continues. All patients who received renal grafts at the National Renal Transplant Centre, Dublin, between January 1992 and December 1999 were retrospectively analyzed. During this time period, patients who were CMV positive and/or had received grafts from CMV-positive donors were administered prophylactic oral acyclovir 800 mg thrice daily, adjusted for calculated creatinine clearance, from the first day post-transplantation. This treatment was continued for three months unless the graft failed or the patient developed CMV disease or died. Graft and patient outcomes were compared in recipients who received acyclovir with those who did not. Over the study period, 935 patients received renal transplants in our center, of whom 487 were administered acyclovir. The incidence of CMV disease was 3.3 cases per 100 patients per annum in those who required prophylaxis. Despite prophylaxis, graft outcomes were found to be significantly worse (p value < 0.001) in the group that qualified for acyclovir. We conclude that acyclovir provides incomplete protection from the negative impact of CMV on graft survival.
Collapse
|
3
|
Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of Cytomegalovirus Disease and Acute Rejection with Graft Loss in Kidney Transplantation. Transplantation 2004; 78:1036-41. [PMID: 15480171 DOI: 10.1097/01.tp.0000137105.92464.f3] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Cytomegalovirus (CMV) and acute rejection (AR) alone have been associated with an increased risk of graft loss in kidney transplantation. However, little is known about their association with graft loss when both affect the transplant recipient. METHODS By using the dynamic time-varying covariate approach to the Cox-proportional hazards model, we retrospectively analyzed the strength of association of AR and CMV disease on graft loss in a single-center kidney and simultaneous pancreas-kidney transplant population. RESULTS Between January 1990 and December 2000, 2,740 kidney and simultaneous pancreas-kidney transplants were performed at the authors' center. The overall 5-year incidence of biopsy-proven AR and CMV disease was 45.8% (n=1,254) and 15.3% (n=420), respectively. The risk ratio (RR) for graft loss was increased by the presence of AR (RR=3.7; P<0.0001), CMV disease (RR=1.9; P=0.0007), AR following CMV disease (RR=6.6; P<0.0001), and CMV disease following AR (RR=3.3; P<0.0001). In patients with AR and CMV disease the average time until AR occurred was longer (441 days) when AR followed CMV disease in comparison with when AR preceded CMV disease (47 days). After adjusting for time-dependent risk of AR for kidney graft loss, the order of AR and CMV disease had no association with graft loss (RR=1.2; P=0.5055). CONCLUSIONS These results demonstrate the strength of AR and CMV disease as prognosticators of impeding kidney graft loss in transplant recipients. Although AR usually precedes CMV disease, the order of AR and CMV disease has no impact on kidney graft loss in kidney and simultaneous pancreas-kidney transplant recipients.
Collapse
Affiliation(s)
- Philipp C Nett
- Division of Organ Transplantation, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
| | | | | | | | | |
Collapse
|
4
|
Squifflet JP, Legendre C. The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis 2002; 186 Suppl 1:S116-22. [PMID: 12353196 DOI: 10.1086/342961] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Cytomegalovirus (CMV) infection and disease, with its extensive direct and indirect consequences, adds considerably to the cost of patient management in both solid organ and bone marrow transplantation. Antiviral prophylaxis for CMV infection can offer cost advantages over preemptive therapy and "wait-and-treat" approaches. Valacyclovir has demonstrated efficacy for CMV prophylaxis in renal, heart, and bone marrow transplantation and is cost-effective when compared with placebo in renal transplant recipients at high risk of CMV infection. In reducing CMV infection and disease, valacyclovir prophylaxis appears to be associated with reductions in indirect effects of CMV (acute graft rejection, other opportunistic infections) and, if these effects are considered, the potential exists for even greater savings to be made with valacyclovir therapy. Benefits of valacyclovir in transplantation extend beyond CMV to other herpesviruses and may be increased in some clinical situations by prolonging prophylaxis beyond 3 months.
Collapse
|
5
|
Sakhuja V, Jha V, Joshi K, Nada R, Sud K, Kohli HS, Gupta KL, Sehgal S. Cytomegalovirus disease among renal transplant recipients in India. Nephrology (Carlton) 2002. [DOI: 10.1046/j.1440-1797.2002.00094.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
6
|
Guirado L, Herreros MA, Muñoz JM, Rabella N, Facundo C, Agraz I, Díaz M, Diaz JM, Durán F, Solà R. Use of cytomegalovirus antigenemia as a marker for preemptive treatment. Transplant Proc 2002; 34:67-8. [PMID: 11959188 DOI: 10.1016/s0041-1345(01)02668-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- L Guirado
- Renal Transplantation Unit, Puigvert Foundation, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rostaing L, Crespin A, Icart J, Lloveras JJ, Durand D, Martinet O, Didier J. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients. Transpl Int 2001; 7 Suppl 1:S331-5. [PMID: 11271244 DOI: 10.1111/j.1432-2277.1994.tb01384.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Cytomegalovirus (CMV) infections, either primoinfection or reactivation, remain an important problem in organ transplantation. We therefore designed a prospective study in which pre-transplant CMV-positive renal transplant (RT) patients were randomized to receive for 3 months starting immediately after transplantation either acyclovir or nothing. Between April 1992 and January 1993, 53 cadaveric renal transplantations were performed in our institution. The immunosuppressive regimen included anti-thymoglobulins (ATG), azathioprine, steroids and cyclosporine A. Patients randomized in the acyclovir arm received the drug from day 1 to day 90 (D90) intravenously as long as the creatinine clearance was not above 10 ml/min and per os afterwards (3200 mg/day if the creatinine clearance was above 50 ml/min). CMV viraemia tests were systematically performed every 2 weeks until day 90 or when febrile episodes occurred. The patients were 53 adults who received a RT during the study period; 37 were included in the study of which 19 received acyclovir prophylaxis (group A) and 18, no prophylaxis (group B). The two groups did not significantly differ according to sex ratio, recipient's age, number of CMV-negative donors and number of days on ATG (10.76+/-6.16 vs. 8.28+/-4.21 days). There were significantly fewer viraemia episodes in group A (n = 6) than in group B (n = 13, P < 0.05); nevertheless, the percentage of symptomatic CMV viraemia was the same in both groups (35% vs. 38.5%). The onset of CMV viraemia occurred in the same period in both groups (39+/-13.8 days vs. 34.3+/-15 days; P = NS). The number of rejection episodes in the study period was the same in both groups (8 in each). We conclude from this prospective study that post-RT acyclovir prophylaxis reduces significantly the number of CMV viraemia episodes but does not delay their onset. Furthermore, it has no effect upon the percentage of symptomatic viraemias.
Collapse
Affiliation(s)
- L Rostaing
- Service de Néphrologie, Unité de Transplantation d'Organes, CHU Rangueil, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
8
|
Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70:1174-80. [PMID: 11063336 DOI: 10.1097/00007890-200010270-00008] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Although specific therapy is available with ganciclovir, cytomegalovirus (CMV) disease remains a major problem after renal transplantation especially in CMV seronegative recipients of organs of seropositive donors (D+R-). METHODS In an open-labeled prospective controlled trial we evaluated the effect of long-term oral ganciclovir prophylaxis (3 g/day for 3 months posttransplantation) in a cohort of 31 CMV-high risk (D+R-) renal transplant recipients (GC) compared with a cohort of 28 high-risk patients with targeted CMV prophylaxis (CO) receiving i.v. ganciclovir during antirejection therapy. Primary end-points were CMV infection, diagnosed by pp65 antigenemia assay or serologic method, and CMV disease. Additionally severity of CMV disease quantified by a scoring system was evaluated. RESULTS CMV prophylaxis significantly reduced the incidence of CMV infection (CO: 75%, GC: 45%; P<.05) and CMV disease (CO: 60%, GC: 29%; P<.05) without relevant side effects and without any clinical suspicion of ganciclovir resistance. Severity of CMV disease as quantified by a scoring system was reduced from 8.3+/-6.7 points in controls to 3.3+/-2.6 points in ganciclovir-treated patients (P<.05). Mortality did not differ significantly between the two groups (CO: n=3, GC: n=1; NS). However, there was one lethal CMV disease and a second death possibly attributable to CMV disease in the control group, whereas in ganciclovir-treated patients there was no CMV-associated fatal outcome. CONCLUSION Long-term oral ganciclovir prophylaxis is effective and safe in CMV high-risk renal transplant recipients.
Collapse
Affiliation(s)
- J Kletzmayr
- Department of Medicine, University of Vienna, Austria.
| | | | | | | | | | | |
Collapse
|
9
|
Mauskopf JA, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. PHARMACOECONOMICS 2000; 18:239-251. [PMID: 11147391 DOI: 10.2165/00019053-200018030-00004] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
BACKGROUND Cytomegalovirus (CMV) disease may occur following renal transplantation and has been shown to have health and cost consequences in this setting. OBJECTIVE To compare the cost effectiveness of different CMV management strategies for renal transplant patients: prophylaxis with (i) oral valaciclovir or (ii) intravenous ganciclovir; viral testing for CMV followed by (iii) pre-emptive therapy with intravenous ganciclovir or (iv) adjustment of immunosuppression and intensive monitoring; or (v) waiting to treat when CMV disease develops. METHODS A decision-tree model was constructed that included the different management strategies for the donor seropositive/recipient seronegative (D+R-) population. Clinical outcomes for the D+R- population came from clinical trials. Treatment algorithms and costs for CMV syndrome and tissue invasive disease were developed from published literature and UK physician interviews. One- and 2-way sensitivity analyses were performed. STUDY PERSPECTIVE UK National Health Service. RESULTS Prophylaxis with either oral valaciclovir or intravenous ganciclovir dominated (lower costs and fewer cases of CMV disease) the pre-emptive treatment and wait-and-treat strategies. The cost per patient was from 157 Pounds to 438 Pounds higher with oral valaciclovir prophylaxis compared with intravenous ganciclovir prophylaxis and the incremental cost per case of CMV disease avoided with valaciclovir prophylaxis ranged from 2243 Pounds to 8111 Pounds (1996 values). These results are sensitive to the efficacy of intravenous ganciclovir prophylaxis and CMV management costs. CONCLUSIONS For D+R- renal transplant patients, prophylaxis is the dominant (more effective and less costly) management strategy compared with pre-emptive and wait-and-treat strategies. The cost per patient with oral valaciclovir prophylaxis compared with intravenous ganciclovir prophylaxis is slightly higher in our base case scenario, but may be lower under reasonable alternative assumptions.
Collapse
Affiliation(s)
- J A Mauskopf
- Research Triangle Institute, Research Triangle Park, North Carolina, USA.
| | | | | | | |
Collapse
|
10
|
Wierzbicki WB, Hagmeyer KO. Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease. Pharmacotherapy 2000; 20:52-63. [PMID: 10641975 DOI: 10.1592/phco.20.1.52.34659] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We conducted a MEDLINE search of the English-language literature from 1966-1999 on the association of chronic infections with Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus (CMV) with coronary heart disease (CHD); additional literature was retrieved from references of selected articles. All human studies were included. Abstracts were excluded because of limited data. Chronic infections in CHD are speculated to be due to serum antibody concentrations of one or more of the three organisms. Data for H. pylori and CMV are difficult to interpret due to the confounding factor of childhood poverty and studies conducted in transplant recipients, respectively. Chlamydia pneumoniae data appear stronger with elevated IgG antibody titers (> or = 64) as a risk factor. Larger prospective studies are warranted to determine an association with CHD before universal prophylaxis or treatment of these chronic infections.
Collapse
Affiliation(s)
- W B Wierzbicki
- Department of Pharmacy Practice, University of Toledo, Ohio, USA
| | | |
Collapse
|
11
|
SHANLEY JOHND. CYTOMEGALOVIRUS. Sex Transm Dis 2000. [DOI: 10.1016/b978-012663330-6/50011-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Déchanet J, Merville P, Lim A, Retière C, Pitard V, Lafarge X, Michelson S, Méric C, Hallet MM, Kourilsky P, Potaux L, Bonneville M, Moreau JF. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103:1437-49. [PMID: 10330426 PMCID: PMC408467 DOI: 10.1172/jci5409] [Citation(s) in RCA: 257] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/1998] [Accepted: 04/12/1999] [Indexed: 01/14/2023] Open
Abstract
In normal individuals, gammadelta T cells account for less than 6% of total peripheral T lymphocytes and mainly express T-cell receptor (TCR) Vdelta2-Vgamma9 chains. We have previously observed a dramatic expansion of gammadelta T cells in the peripheral blood of renal allograft recipients only when they developed cytomegalovirus (CMV) infection. This increase was long lasting (more than 1 year), was associated with an activation of gammadelta T cells, and concerned only Vdelta1 or Vdelta3 T-cell subpopulations. Analysis of gammadelta TCR junctional diversity revealed that CMV infection in these patients was accompanied by (a) a marked restriction of CDR3 size distribution in Vdelta3 and, to a lesser extent, in Vdelta1 chains; and (b) a selective expansion of Vdelta1 cells bearing recurrent junctional amino acid motifs. These features are highly suggestive of an in vivo antigen-driven selection of gammadelta T-cell subsets during the course of CMV infection. Furthermore, Vdelta1 and Vdelta3 T cells from CMV-infected kidney recipients were able to proliferate in vitro in the presence of free CMV or CMV-infected fibroblast lysates but not uninfected or other herpes virus-infected fibroblast lysates. This in vitro expansion was inhibited by anti-gammadelta TCR mAb's. These findings suggest that a population of gammadelta T cells might play an important role in the immune response of immunosuppressed patients to CMV infection.
Collapse
Affiliation(s)
- J Déchanet
- Centre National de la Recherche Scientifique UMR 5540, Université Bordeaux 2, FR60, 33076 Bordeaux, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- J Déchanet
- CNRS UMR 5540, Université Bordeaux 2, France
| | | | | | | | | |
Collapse
|
14
|
Birkeland SA, Andersen HK, Gahrn-Hansen B. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1998; 30:221-6. [PMID: 9790127 DOI: 10.1080/00365549850160837] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
METHOD Since 1990, we have treated all kidney transplanted patients with cyclosporin (CsA)+ an initial 10 d antilymphocyte globulin (ALG) course, from September 1995 supplemented with mycophenolate mofetil (MMF). In 170 consecutive transplantations from June 1992 to the end of 1996, aciclovir 3200 mg/d (adjusted for kidney function and in children to age) was given prophylactically for 3 months post-transplantation (Tx), monitored with systematic and frequent tests for HSV and CMV. In case of CMV infection, we gave ganciclovir intravenously (oral ganciclovir from 1996) in doses according to kidney function for 3 months, followed by a further 3 months observation and monitoring period. In case of acute cellular rejection, ganciclovir was given during the 10-d OKT3 course and 1 week further. In case of delayed graft function combined with aciclovir side effects, ganciclovir was given until aciclovir could be reintroduced. RESULTS 39% were HSV seronegative at Tx. There were no seroconversions or reactivations within the observation period. No mucocutaneous HSV infections was observed. No resistant strains developed. 26% were both HSV and CMV negative at Tx. 52% were CMV negative at Tx. 30% experienced a CMV infection post-transplant. The patients were grouped according to CMV status in the donor (D) and recipient (R) before Tx. We found approximately the same number of patients in the 4 CMV groups D-/R-, D+/R-, D-/R+ and D+/R+. Most infections occurred in the D+/R- group compared to D-/R- (p = 0.009). A significant increase in the number of CMV infections occurred in this subgroup when we gave reduced doses in case of delayed graft function (p = 0.015), from 1994. We observed only 1 CMV disease (in 1992). Serological EBV testing were performed concomitantly. No correlation was seen between CMV and EBV infections. From September 1995 we have treated all transplanted patients (n = 40) with CsA/ALG/MMF. We found no significant increase in CMV infections in this group. CONCLUSIONS Prophylaxis with aciclovir (combined with ganciclovir during acute rejections and in case of delayed graft function with aciclovir side effects) gives a good protection against HSV and CMV infections and prevents CMV disease effectively. High-dose aciclovir post-transplantation (or shift to ganciclovir) seems to be important to obtain effective prophylaxis. Better immunosuppression with MMF does not result in more CMV infections.
Collapse
Affiliation(s)
- S A Birkeland
- Department of Nephrology, Odense University Hospital, Denmark
| | | | | |
Collapse
|
15
|
Ginevri F, Losurdo G, Fontana I, Rabagliati AM, Bonatto L, Valente R, Venzano P, Nocera A, Basile G, Valente U, Gusmano R. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Transpl Int 1998. [DOI: 10.1111/j.1432-2277.1998.tb01096.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Sayegh MH, Carpenter CB. RENAL TRANSPLANTATION. Immunol Allergy Clin North Am 1996. [DOI: 10.1016/s0889-8561(05)70246-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Sayegh MH, Carpenter CB. RENAL TRANSPLANTATION. Radiol Clin North Am 1996. [DOI: 10.1016/s0033-8389(22)00211-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
|
19
|
Strategies for the treatment and prevention of cytomegalovirus infections. Int J Antimicrob Agents 1993; 3:187-204. [DOI: 10.1016/0924-8579(93)90012-t] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/1993] [Indexed: 11/19/2022]
|